Captured pumpkin in Kingston Ontario Canada
Captured this pumpkin and decided with my heart still hurting from the loss of a family friend three days ago with his battle with cancer and other people and friends i know who are suffering with cancer.This is close to my heart and i know there is probably not one of you out there in Reddbubble who has no heard or even lost a loved one to cancer..We are all aware of this horrible disease and what it can do when someone gets cancer we all do for its affects us all..I pray for a cure for cancer and iv provided a link next to my home town they came up with a vaccine to kill most cancers have a read of it this would be a wonderful miracle wouldnt it??
*I looked at this pumpkin and i thought why not all i could see was pink pink pink,so i followed my heart and did this up in pink in dedication to all suffering from cancer and for our family friend,,and little girl of five who passed away from cancer and to a dear friend Suzan who is battling so hard for her life hopitalized for about a year battling cancer.My heart thoughts and prayer are for all who suffer from this and a cure can’t come soon enough..God be with all there private and individual needs of all with this horrible disease Cancer..
Ottawa-made virus shows promise as cancer treatment
New drug, JX594, engineered from smallpox vaccine
*An experimental, made-in-Ottawa virus that attacks tumours has been shown to be a safe and potentially useful drug against hard-to-treat cancers, justifying further trials in more patients.
Early results even raise the possibility that the treatment could actually prevent the spread of tumours – a long-desired goal in the hunt for better cancer therapies.
John Bell, a senior scientist at The Ottawa Hospital Research Institute and University of Ottawa, is working on a cancer-killing virus genetically engineered from a version used to vaccinate against smallpox.
In the first phase of a lengthy process to test the drug’s safety and effectiveness, the virus-based drug, called JX594, appeared to cause no lasting harm to cancer patients whose tumours were resistant to conventional chemotherapy and radiation.
The only observed side effects were flu-like symptoms, such as fever, chills, fatigue, headache, nausea and vomiting, which lasted up to 24 hours and could be treated with over-the-counter drugs such as acetaminophen. “There were no long-term side effects that we could see at all,” said Bell.
More significantly, the virus showed signs of quickly infecting and killing cancer cells, while protecting healthy cells, which current therapies can’t do.
The virus also appeared as capable of attacking isolated tumours as those spread throughout the body, which are the toughest to treat.
Bell’s team proved this by injecting the virus into the bloodstreams of 23 terminal cancer patients, all with metastatic tumours that had resisted standard forms of treatment. The only cancer the virus couldn’t fight was leukemia.
Within two weeks of receiving a single dose of the drug, biopsies showed the tumour-fighting virus was multiplying in seven of the patients who were given the highest dosages. And scans later showed that tumours in six of the patients were shrinking or had stopped growing.
The results of the Phase 1 trial, in which a drug’s safety for patients is assessed, were published Wednesday in Nature, a top science journal. Because only a handful of patients were studied in the trial, Bell and his research team must do further tests on hundreds more patients to show the treatment actually works.
Some biologists have expressed skepticism about cancer-targeting viruses, saying the body’s immune system would kill the virus before it could kill the tumours.
Indeed, Bell acknowledged the possibility that patients who are given repeated doses of the virus could develop such potent immunity to it that the treatment no longer works. For that reason, he is in the early stages of testing second-line viruses that could replace JX594.
However, Bell’s research team has also shown that the virus-based drug can stimulate the body’s immune system to recognize and attack tumours and, perhaps, even prevent them from redeveloping once killed.
That raises the possibility that the treatment could actually stop the spread of tumours.
“In mouse models, we’ve shown that if we treat with this virus and cure the tumour in mice, the mice develop immunity to the tumour,” said Bell. “The question is, will we see that in people? We don’t know the answer to that yet.”
Cancer-killing viruses have a long and checkered history in cancer therapy – perceived as safe but ineffective. To date, no cancer-targeting virus has been approved as a treatment for the disease.
Yet interest in such viruses was revived earlier this year, when the U.S. biotechnology giant Amgen paid $425 million to acquire BioVex, a Massachusetts-based company that is in the final phase of testing a tumour-busting virus.
Approval of Amgen’s virus by U.S. drug regulators would significantly improve the prospects for Bell’s own virus.
Bell has established a San Francisco-based spin-off company, Jennerex Inc., to commercialize his experimental therapy.
A Phase 2 trial is to start this month for up to 140 patients in Canada, the U.S., Korea and Europe. It is aimed at patients with end-stage liver or colon cancer, who will be randomly assigned to receive either the experimental treatment, or standard forms of therapy.
In order for the virus to be approved for commercial use, the trial must determine if the virus can prolong a patient’s life for longer than existing therapies can. The current prognosis for most liver-cancer patients is six months. "We’re hoping to do better than that with our therapy*
Family Friend who passed away yesterday from Cancer Sept.29/11Below did this up to put in paper and funeral home
D’FANTIS, Dennis – After a courageous fight with cancer, Dennis passed away peacefully surrounded by those who loved him at the Kingston General Hospital on Thursday, September 29, 2011 in his 67th year. Survived by his beloved wife Marianne of 46 years. Loving father of Denise (Simon), Conni (Chris), Julie (Rob) and Teddy (Jen). He will be missed by grandchildren Johnny, Kaitlyn, Kalen, Maddie, Noah, Mariana, Isiah and Jada. Brother of Edna (Nick) and Sam (Ellen). Son-in-law of Helen. Dennis will be greatly missed by all that knew him. Resting at JAMES REID FUNERAL HOME (1900 John Counter Boulevard) Monday, October 3, 2011 2-4 p.m. and 7-9 p.m. Funeral service will be held in St. Peter’s Anglican Church (4333 Bath Road) on Tuesday, October 4, 2011 at 11 am., Rev. Mike Michielin officiating. As expressions of sympathy, memorial donations to St. Peter’s Anglican Church or the Kingston Humane Society would be appreciated